Tempus AI teams with Genialis to develop RNA-based biomarker algorithms
Tempus AI (TEM), announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types…Tempus multimodal dataset has already proved pivotal in the launch of Genialis krasID, the first commercially available algorithm that stratifies patients who benefit from KRAS inhibition… “We look forward to working with Genialis and demonstrating new ways in which our data can be applied to further a new kind of research, one that embraces the power that RNA-based biomarkers can have on the future of cancer care,” said Kate Sasser, Ph.D., Chief Scientific Officer at Tempus. “Multimodal algorithms, including RNA signatures, are demonstrating rapid advancement in clinical utility for personalized treatment decisions, and we are excited to partner with Genialis to fuel this data-driven precision medicine future with our xR assay and vast multimodal dataset.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TEM:
- Tempus AI up after FDA issues draft guidance on AI use in drug decision making
- tempus AI Inc Class A call volume above normal and directionally bullish
- Cathie Wood’s ARK Investment bought 348K shares of Tempus AI today
- Cathie Wood’s ARK Investment bought 335.7K shares of Tempus AI today
- Cathie Wood’s ARK Investment bought 317.6K shares of Tempus AI today
